Axon Connected
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Axon Connected - overview
Established
2013
Location
Harrisonburg, VA, US
Primary Industry
Medical Devices & Equipment
About
Axon Connected specializes in innovative healthcare solutions, focusing on immune enhancement and advanced diagnostic technologies to improve patient outcomes in oncology and women’s health. Founded in 2013 and headquartered in Harrisonburg, US, Axon Connected develops healthcare technologies including the immune system enhancement drug AxImmune and AI-powered diagnostic tools. The company raised USD 2. 1 million in Series B financing on January 11, 2015, and has completed one deal to date.
Kent Murphy leads the company as CEO. Axon Connected's primary offerings encompass innovative solutions aimed at improving healthcare and operational efficiencies. Their flagship product, AxImmune, enhances immune function for cancer patients treated with Immune Checkpoint Inhibitors. The company also offers AxonDx, an AI-powered fluorescent microscope for detecting cancer materials, Axon Optics targeted at telecommunications, and Caza Health focusing on AI-driven diagnostic equipment for women's health, serving healthcare institutions and research facilities primarily in North America and Europe.
The revenue structure for Axon Connected is defined by partnerships and direct engagements with healthcare providers and industry stakeholders. Revenue is generated through B2B agreements and client contracts, including research collaborations and licensing agreements. AxImmune targets oncology practices, while AxonDx serves hospitals needing refined diagnostic tools. The company employs a pricing strategy reflecting the value of its technologies, with potential subscription models for its software and support services.
Axon Connected aims to launch new products designed to enhance its portfolio, specifically in immune and diagnostic technologies. The company is targeting expansion into European and Asian markets by 2025, leveraging its recent Series B funding of USD 2. 1 million raised in January 2015 to support these initiatives. This funding will facilitate the development of its flagship products and enhance market reach.
Primary Industry
Medical Devices & Equipment
Sub Industries
Medical Devices & Equipment
Website
www.axonconnected.com
Verticals
HealthTech
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.